Keywords
Dermatomyositis
Breast Neoplasms
Paraneoplastic Syndromes
Breast Neoplasms
Paraneoplastic Syndromes
How to Cite
Sosa-Vega, C. D., Pardo-Parra, L. M., Matínez-León, S. E., Camargo - Tarazona, D. R., & Niño-Rodríguez, Álvaro E. (2018). Dermatomyositis associated with breast cancer: Clinical characteristics, complications and treatment. Médicas UIS, 31(2), 41–47. https://doi.org/10.18273/revmed.v31n2-2018005
Abstract
Breast cancer is an important public health problem. Dermatomyositis is an infrequent paraneoplastic syndrome of breast cancer. It is necessary that the clinician has knowledge on how to diagnose and treat it properly. The aim of this article is to review the literature on the clinical, complications and treatment of dermatomyositis in breast cancer. A search was made in electronic databases, including a total of 34 articles, covering randomized clinical trials, meta-analyzes, original descriptive and analytical articles and case reports. Dermatomyositis can occur before, during, or after breast cancer. Pulmonary complications are frequent, and they can be lethal. Dermatomyositis increases the complications of radiotherapy and mortality in patients with breast cancer. The pharmacological treatment consists of glucocorticoid
application at doses according to the patient’s need. MÉD.UIS. 2018;31(2):41-7
References
1. Organización mundial de la salud. Cáncer de mama: prevención y control. OMS [Internet]. 2017 [citado 19 de Abril del 2017]. Disponible en: http://www.who.int/topics/cancer/breastcancer/es/.
2. Organización panamericana de la salud. Cáncer de mama. OPS [Internet]. 2017 [citado 19 de Abril del 2017]. Disponible en: http://www.paho.org/hq/index.php?option=com_content&view=category&id=3400&layout=blog&Itemid=3639&lang=es.
3. World health organization. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. WHO [Internet]. 2016 [citado 19 de Abril del 2016]. Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
4. Arrospide A, Soto-Gordoa M, Acaiturri T, López-Vivanco G, Abecia L, Mar J. Costo del tratamiento del cáncer de mama por estadío clínico en el País Vasco. Rev. Esp. Salud Pública. 2015;89(1):93-97.
5. Instituto Nacional de Cancerología-ESE. Incidencia, mortalidad y prevalencia de cáncer en Colombia 2007- 2011. INC [Internet]. 2011 [citado 19 de Abril del 2017]. Disponible en: http://www.cancer.gov.co/files/libros/archivos/incidencia1.pdf
6. World health organization (WHO). GLOBOCAN: Cancer Incidence in Five Continents, Vol. XI. [Internet] 2012. [citado el 19 de abril del 2017]. Disponible en: http://ci5.iarc.fr/Default.aspx.
7. Martínez E, Sánchez A, García A, Dueñas R, Lozano A. Dermatomiositis en el diagnóstico del cáncer: carcinoma de mama y de vesícula biliar. Oncología (Barc.).2005;28(4):31-4.
8. Murgić J, Prpić M, Kirac I, Camino-Varela AM, Bolanca A, Kusić Z. Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer. Coll Antropol. 2012;36(1):325-9.
9. Song YJ, Wu YF, Fan T. Dermatosis as the Initial Manifestation of Malignant Breast Tumors: Retrospective Analysis of 4 Cases. Breast Care. 2010;5(3):174-6.
10. Levine D, Miller S, Al-Dawsari N, Barak O, Gottlieb AB. Paraneoplastic dermatoses associated with gynecologic and breast malignancies. Obstet Gynecol Surv. 2010;65(7):455-61.
11. Miller FW, Cooper RG, Vencovský J, Rider LG, Danko K, Wedderburn LR, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65(12):3239-47.
12. Zhang CE, Li Y, Wang ZX, Gao JP, Zhang XG, Zuo XB, et al. Variation at HLA-DPB1 is associated with dermatomyositis in Chinese population. J Dermatol. 2016;43(11):1307-13.
13. Blanco MC, Figueroa L, García F, Francis ML, Carrasco A, Correia MA, et al. Dermatomiositis como síndrome paraneoplásico del carcinoma medular de tiroides esporádico. Rev Venez Endocrinol Metab. 2006;4(3):61-61.
14. Dias LP, Faria AL, Scandiuzzi MM, Inhaia CL, Shida JY, Gebrim LH. A rare case of severe myositis as paraneoplastic syndrome on breast cancer. World J Surg Oncol. 2015;13(1):134-9.
15. Pectasides D, Koumpou M, Gaglia A, Pectasides M, Lambadiari V, Lianos E, et al. Dermatomyositis associated with breast cancer. Anticancer Res. 2006;26(3B):2329-31.
16. Consejo salubridad general de México. Diagnóstico y tratamiento de polimiositis y dermatomiositis. [Internet]. 20** [citado numero de mes de año]. Disponible en: URL:http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/477_GPC_Dermatomiositis/GRR_Dermatomiositis_y_Polimiositis.pdf
17. Medsger TA, Oddis CV. Classification and diagnostic criteria for polymyositis and dermatomyositis. J Rheumatol.1995;22(4):581-5.
18. Osako T, Ito Y, Morimatsu A, Tada K, Sakurai N, Takahashi S, etal. Flare-up of dermatomyositis along with recurrence of breast cancer. Breast J.2007;13(2):200-202.
19. Noyola JR, Figueroa C, Rodríguez F, Cuéllar R. Tratamiento de la dermatomiositis con metrotexate. Una alternativa terapéutica. Hond. Ped.1995;18(1):3-7.
20. Nishioka M, Igawa K, Yahata Y, Tani M, Katayama I. Simultaneous occurrence of dermatomyositis and systemic sarcoidosis with recurrent breast cancer. J Dermatol.2012;39(5):485-6.
21. Yeh CN, Chen SC, Hwang TL, Chen MF, Liaw CC, Chan HL. Breast carcinoma in patients with dermatomyositis: a retrospective analysis of eight cases. Chang Gung Med J. 2002;25(6):374-80.
22. Seishima M, Shimizu H, Oyama Z. Skin metastasis of breast cancer clinically undistinguished from amyopathic dermatomyositis. Eur J Dermatol. 2001;11(2):131-133.
23. Restrepo M, González LA, Pantoja AE, Ramírez LA, Vásquez GM. Complicaciones pulmonares de las miopatías inflamatorias idiopáticas: a propósito de un caso con miopatía diafragmática. Rev Colomb Reumatol. 2009;16(3):301-309.
24. Bakhshaee M, Jokar MH, Mirfeizi Z, Atabati E, Tarighat S. Subcutaneous emphysema, pneumomediastinum and pneumothorax in a Patient with Dermatomyositis. Iran J Otorhinolaryngol. 2017;29(91):113-116.
25. Allaoui A, Aboudib F, Bouissar W, Echchilali K, Moudatir M, Alaoui FZ, et al. Spontaneous pneumomediastinum: A rare complication of dermatomyositis. Rev Pneumol Clin. 2017;73(5):258-262.
26. Zhen-Guo H, Min-Xing Y, Xiao-Liang C, Ran Y, He C, Bao-Xiang G, et al. Value of whole-body magnetic resonance imaging for screening multifocal osteonecrosis in patients with polymyositis/dermatomyositis. Br J Radiol. 2017;90(1073):1-34.
27. Akbaryan M, Darabi F, Soltani Z. Dermatomyositis leading to necrotizing vasculitis: a perfect response to applied therapy. Int J Biomed Sci. 2016;12(4):125-9.
28. Park JK, Yang JA, Ahn EY, Chang SH, Song YW, Curtis JR, et al. Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. BMC Cancer. 2016;16(381):1-9.
29. Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer. 2008;113(3):648-53.
30. Callen JP. Dermatomyositis and multiple malignancies in a patient treated with methotrexate. J Surg Oncol. 1983;24(2):113-6.
31. Fabiani LR. tratamiento de la dermatomiositis. scientifica. 2008;6(1):1-4.
32. Martiarena A, Aldamiz-Echebarria M, Martínez C, García JJ. Actualización en el tratamiento de la dermatomiositis: a propósito de un caso. Farm Hosp. 2014;38(6):489-491.
33. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012;14(1):1-9.
34. Mebazaa A, Boussen H, Nouira R, Gamoudi A, Rahal K, Kamoun MR, et al. Dermatomyositis and breast cancer: a multicenter Tunisian retrospective study of 13 cases. Tunis Med. 2011;89(1):18-22.
2. Organización panamericana de la salud. Cáncer de mama. OPS [Internet]. 2017 [citado 19 de Abril del 2017]. Disponible en: http://www.paho.org/hq/index.php?option=com_content&view=category&id=3400&layout=blog&Itemid=3639&lang=es.
3. World health organization. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. WHO [Internet]. 2016 [citado 19 de Abril del 2016]. Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
4. Arrospide A, Soto-Gordoa M, Acaiturri T, López-Vivanco G, Abecia L, Mar J. Costo del tratamiento del cáncer de mama por estadío clínico en el País Vasco. Rev. Esp. Salud Pública. 2015;89(1):93-97.
5. Instituto Nacional de Cancerología-ESE. Incidencia, mortalidad y prevalencia de cáncer en Colombia 2007- 2011. INC [Internet]. 2011 [citado 19 de Abril del 2017]. Disponible en: http://www.cancer.gov.co/files/libros/archivos/incidencia1.pdf
6. World health organization (WHO). GLOBOCAN: Cancer Incidence in Five Continents, Vol. XI. [Internet] 2012. [citado el 19 de abril del 2017]. Disponible en: http://ci5.iarc.fr/Default.aspx.
7. Martínez E, Sánchez A, García A, Dueñas R, Lozano A. Dermatomiositis en el diagnóstico del cáncer: carcinoma de mama y de vesícula biliar. Oncología (Barc.).2005;28(4):31-4.
8. Murgić J, Prpić M, Kirac I, Camino-Varela AM, Bolanca A, Kusić Z. Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer. Coll Antropol. 2012;36(1):325-9.
9. Song YJ, Wu YF, Fan T. Dermatosis as the Initial Manifestation of Malignant Breast Tumors: Retrospective Analysis of 4 Cases. Breast Care. 2010;5(3):174-6.
10. Levine D, Miller S, Al-Dawsari N, Barak O, Gottlieb AB. Paraneoplastic dermatoses associated with gynecologic and breast malignancies. Obstet Gynecol Surv. 2010;65(7):455-61.
11. Miller FW, Cooper RG, Vencovský J, Rider LG, Danko K, Wedderburn LR, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65(12):3239-47.
12. Zhang CE, Li Y, Wang ZX, Gao JP, Zhang XG, Zuo XB, et al. Variation at HLA-DPB1 is associated with dermatomyositis in Chinese population. J Dermatol. 2016;43(11):1307-13.
13. Blanco MC, Figueroa L, García F, Francis ML, Carrasco A, Correia MA, et al. Dermatomiositis como síndrome paraneoplásico del carcinoma medular de tiroides esporádico. Rev Venez Endocrinol Metab. 2006;4(3):61-61.
14. Dias LP, Faria AL, Scandiuzzi MM, Inhaia CL, Shida JY, Gebrim LH. A rare case of severe myositis as paraneoplastic syndrome on breast cancer. World J Surg Oncol. 2015;13(1):134-9.
15. Pectasides D, Koumpou M, Gaglia A, Pectasides M, Lambadiari V, Lianos E, et al. Dermatomyositis associated with breast cancer. Anticancer Res. 2006;26(3B):2329-31.
16. Consejo salubridad general de México. Diagnóstico y tratamiento de polimiositis y dermatomiositis. [Internet]. 20** [citado numero de mes de año]. Disponible en: URL:http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/477_GPC_Dermatomiositis/GRR_Dermatomiositis_y_Polimiositis.pdf
17. Medsger TA, Oddis CV. Classification and diagnostic criteria for polymyositis and dermatomyositis. J Rheumatol.1995;22(4):581-5.
18. Osako T, Ito Y, Morimatsu A, Tada K, Sakurai N, Takahashi S, etal. Flare-up of dermatomyositis along with recurrence of breast cancer. Breast J.2007;13(2):200-202.
19. Noyola JR, Figueroa C, Rodríguez F, Cuéllar R. Tratamiento de la dermatomiositis con metrotexate. Una alternativa terapéutica. Hond. Ped.1995;18(1):3-7.
20. Nishioka M, Igawa K, Yahata Y, Tani M, Katayama I. Simultaneous occurrence of dermatomyositis and systemic sarcoidosis with recurrent breast cancer. J Dermatol.2012;39(5):485-6.
21. Yeh CN, Chen SC, Hwang TL, Chen MF, Liaw CC, Chan HL. Breast carcinoma in patients with dermatomyositis: a retrospective analysis of eight cases. Chang Gung Med J. 2002;25(6):374-80.
22. Seishima M, Shimizu H, Oyama Z. Skin metastasis of breast cancer clinically undistinguished from amyopathic dermatomyositis. Eur J Dermatol. 2001;11(2):131-133.
23. Restrepo M, González LA, Pantoja AE, Ramírez LA, Vásquez GM. Complicaciones pulmonares de las miopatías inflamatorias idiopáticas: a propósito de un caso con miopatía diafragmática. Rev Colomb Reumatol. 2009;16(3):301-309.
24. Bakhshaee M, Jokar MH, Mirfeizi Z, Atabati E, Tarighat S. Subcutaneous emphysema, pneumomediastinum and pneumothorax in a Patient with Dermatomyositis. Iran J Otorhinolaryngol. 2017;29(91):113-116.
25. Allaoui A, Aboudib F, Bouissar W, Echchilali K, Moudatir M, Alaoui FZ, et al. Spontaneous pneumomediastinum: A rare complication of dermatomyositis. Rev Pneumol Clin. 2017;73(5):258-262.
26. Zhen-Guo H, Min-Xing Y, Xiao-Liang C, Ran Y, He C, Bao-Xiang G, et al. Value of whole-body magnetic resonance imaging for screening multifocal osteonecrosis in patients with polymyositis/dermatomyositis. Br J Radiol. 2017;90(1073):1-34.
27. Akbaryan M, Darabi F, Soltani Z. Dermatomyositis leading to necrotizing vasculitis: a perfect response to applied therapy. Int J Biomed Sci. 2016;12(4):125-9.
28. Park JK, Yang JA, Ahn EY, Chang SH, Song YW, Curtis JR, et al. Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. BMC Cancer. 2016;16(381):1-9.
29. Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer. 2008;113(3):648-53.
30. Callen JP. Dermatomyositis and multiple malignancies in a patient treated with methotrexate. J Surg Oncol. 1983;24(2):113-6.
31. Fabiani LR. tratamiento de la dermatomiositis. scientifica. 2008;6(1):1-4.
32. Martiarena A, Aldamiz-Echebarria M, Martínez C, García JJ. Actualización en el tratamiento de la dermatomiositis: a propósito de un caso. Farm Hosp. 2014;38(6):489-491.
33. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012;14(1):1-9.
34. Mebazaa A, Boussen H, Nouira R, Gamoudi A, Rahal K, Kamoun MR, et al. Dermatomyositis and breast cancer: a multicenter Tunisian retrospective study of 13 cases. Tunis Med. 2011;89(1):18-22.
Downloads
Download data is not yet available.